What should be done if a patient on a GLP‑1 receptor agonist develops mucus in the stool?

GLP-1 Use and Mucus in Stool

Mucus in stool while on GLP-1 receptor agonists warrants immediate evaluation to rule out infectious or inflammatory colitis, but is not a recognized direct adverse effect of these medications in the available evidence.

Initial Assessment

When a patient on GLP-1 therapy reports mucus in stool, you need to determine whether this represents:

• Infectious colitis (most common concern)
• Inflammatory bowel disease or immune-mediated colitis (if on concurrent immunotherapy)
• Small intestinal bacterial overgrowth (SIBO) - emerging concern with GLP-1 use
• Unrelated gastrointestinal pathology

Diagnostic Workup

Immediately obtain:

• Stool studies including culture, ova and parasites, Clostridioides difficile testing
• Fecal calprotectin or lactoferrin (inflammatory markers)
• Complete blood count, CRP/ESR
• Detailed history: duration of symptoms, associated abdominal pain, fever, weight loss, recent antibiotic use

Consider SIBO evaluation if:

• Patient has bloating, abdominal distension, or diarrhea alongside mucus
• Recent evidence 1 demonstrates GLP-1 RAs increase short-term SIBO risk (HR 2.14,95% CI 1.13-4.07) due to impaired gut motility
• Breath testing may be warranted if symptoms persist

GLP-1-Related Gastrointestinal Effects

The known GI adverse events from GLP-1 therapy include 2:

• Nausea and vomiting
• Diarrhea
• Constipation
• Delayed gastric emptying

Mucus in stool is NOT listed as a typical GLP-1 adverse effect in the available guidelines or research. However, GLP-1 agents can alter gut motility, potentially contributing to conditions that present with mucus.

Management Algorithm

If Infectious/Inflammatory Cause Identified:

1. Treat the underlying infection appropriately
2. Continue GLP-1 therapy unless severe symptoms warrant temporary cessation
3. Monitor for resolution with treatment

If SIBO Suspected:

1. Consider breath testing for diagnostic confirmation
2. Treat with appropriate antibiotics (rifaximin ± neomycin)
3. Reassess need for GLP-1 continuation - weigh cardiovascular/glycemic benefits against GI complications 3

If No Clear Cause Found:

1. Do NOT automatically discontinue GLP-1 therapy - these agents provide substantial mortality benefit (HR 0.54-0.61 for cardiovascular death) 3
2. Consider gastroenterology referral for colonoscopy with biopsy if:
   • Symptoms persist beyond 2 weeks
   • Blood in stool develops
   • Constitutional symptoms present
   • Fecal inflammatory markers elevated

Special Considerations

Bowel obstruction risk: Recent case reports 4 link GLP-1 RAs to bowel obstruction in patients with preexisting GI motility disorders. If the patient has:

• History of prior bowel obstruction
• Abdominal pain with distension
• Constipation with mucus

Consider imaging (CT abdomen) to rule out mechanical obstruction before attributing symptoms solely to medication.

Common Pitfall

Do not reflexively stop GLP-1 therapy for isolated mucus in stool. The cardiovascular and mortality benefits are substantial, particularly in patients with established cardiovascular disease. Only discontinue if:

• Severe inflammatory colitis confirmed on endoscopy
• Recurrent bowel obstruction occurs
• SIBO is refractory to treatment and symptoms significantly impair quality of life

The gastrointestinal side effects mentioned in diabetes guidelines 5 (nausea, vomiting, diarrhea) may warrant discontinuation in older adults with unexplained weight loss, but mucus alone does not meet this threshold unless part of a broader inflammatory process.